Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25847910 | 0.88 | HTT (0.43) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL21946926 | 0.83 | HTT (0.60) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL26475122 | 0.80 | CRBN (0.66) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL24890781 | 0.80 | HTT (0.56) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL24890784 | 0.80 | HTT (0.56) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL26518244 | 0.75 | CRBN (0.56) | POLBCRBNDDB1 | |
| SCHEMBL25818971 | 0.75 | CRBN (0.56) | POLBCRBNDDB1 | |
| SCHEMBL26518247 | 0.75 | CRBN (0.56) | POLBCRBNDDB1 | |
| SCHEMBL19585871 | 0.72 | CRBN (0.71) | HTTGAAPOLBKMT2ACRBN | |
| SCHEMBL6819070 | 0.72 | CRBN (0.71) | HTTGAAPOLBKMT2ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | HTT 689/4885GAA 350/4885POLB 1390/4885 |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | HTT 2090/4885GAA 1565/4885POLB 3123/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HTT 689/4885GAA 350/4885POLB 1390/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | HTT 700/4885GAA 387/4885POLB 1827/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | HTT 689/4885GAA 350/4885POLB 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.